Radiotherapy achieves a 79% response rate and preserves vision in 80% of cases.14Targeted therapies, such as erlotinib for EGFR-mutated adenocarcinoma, have shown to improve outcomes. The gene discussed is EGFR; the disease is adenocarcinoma.